Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
In: Rheumatology, Jg. 63 (2024-03-01), Heft 3, S. 772-779
academicJournal
Zugriff:
Objectives Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis in an international cohort (the APS ACTION cohort). Secondly, we aimed to identify clinical and laboratory characteristics associated with damage in aPL-positive patients. Methods In this cross-sectional study, we analysed the baseline damage in aPL-positive patients with or without APS classification. We excluded patients with other autoimmune diseases. We analysed the demographic, clinical and laboratory characteristics based on two subgroups: (i) thrombotic APS patients with high vs low damage; and (ii) non-thrombotic aPL-positive patients with vs without damage. Results Of the 826 aPL-positive patients included in the registry as of April 2020, 586 with no other systemic autoimmune diseases were included in the analysis (412 thrombotic and 174 non-thrombotic). In the thrombotic group, hyperlipidaemia (odds ratio [OR] 1.82; 95% CI 1.05, 3.15; adjusted P = 0.032), obesity (OR 2.14; 95% CI 1.23, 3.71; adjusted P = 0.007), aβ2GPI high titres (OR 2.33; 95% CI 1.36, 4.02; adjusted P = 0.002) and corticosteroid use (ever) (OR 3.73; 95% CI 1.80, 7.75; adjusted P < 0.001) were independently associated with high damage at baseline. In the non-thrombotic group, hypertension (OR 4.55; 95% CI 1.82, 11.35; adjusted P = 0.001) and hyperlipidaemia (OR 4.32; 95% CI 1.37, 13.65; adjusted P = 0.013) were independent predictors of damage at baseline; conversely, single aPL positivity was inversely correlated with damage (OR 0.24; 95% CI 0.075, 0.77; adjusted P = 0.016). Conclusions DIAPS indicates substantial damage in aPL-positive patients in the APS ACTION cohort. Selected traditional cardiovascular risk factors, steroids use and specific aPL profiles may help to identify patients more prone to present with a higher damage burden. [ABSTRACT FROM AUTHOR]
Titel: |
Damage measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in antiphospholipid antibody-positive patients included in the APS ACTION registry.
|
---|---|
Autor/in / Beteiligte Person: | Balbi, Gustavo G M ; Ahmadzadeh, Yasaman ; Tektonidou, Maria G ; Pengo, Vittorio ; Sciascia, Savino ; Ugarte, Amaia ; Belmont, H Michael ; Lopez-Pedrera, Chary ; Fortin, Paul R ; Wahl, Denis ; Gerosa, Maria ; Jesús, Guilherme R de ; Ji, Lanlan ; Atsumi, Tatsuya ; Efthymiou, Maria ; Branch, D Ware ; Nalli, Cecilia ; Almaraz, Esther Rodriguez ; Petri, Michelle ; Cervera, Ricard |
Zeitschrift: | Rheumatology, Jg. 63 (2024-03-01), Heft 3, S. 772-779 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1462-0324 (print) |
DOI: | 10.1093/rheumatology/kead292 |
Schlagwort: |
|
Sonstiges: |
|